Bicara Therapeutics Inc. (BCAX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bicara Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 27.10 $ — 84% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 16.1% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.77 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.38 | – | 0 | – | – | -30 | -30 |
| 2025: Q1 | -0.68 | – | 0 | – | – | -28 | -28 |
| 2025: Q2 | -0.50 | – | 0 | – | – | -26 | -26 |
| 2025: Q3 | -0.67 | – | 0 | – | – | -29 | -29 |
| 2025: Q4 | -0.68 | – | 0 | – | – | -24 | -24 |
| 2026: Q1 | -0.93 | – | 0 | – | – | -38 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Bicara Therapeutics Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entwicklung bifunktionaler Therapien für solide Tumore.
| Employees | 103 |
|---|---|
| Headquarters | Boston, MA |
| Website | bicara.com |
| IPO Date | 13. Sep 2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director | 1990 |
| Ryan Cohlhepp Pharm.D. | President, COO & Director | 1977 |
| Ivan Hyep M.B.A. | CFO & Treasurer | 1985 |
| Rachel Frank | Vice President of Investor Relations and Corporate Communications | – |
| Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary | 1972 |
| Pauline Dufresne | Chief People Officer | – |
| Rachel Salazar | SVP of R&D Strategy and Operations | – |
| Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain | – |
| Angela Windt | VP & Head of Regulatory Affairs | – |
| Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 28 | 29.68 | 831 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 9,972 | 28.42 | 283,367 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Other | 10,000 | 3.79 | 37,898 |
| 21. Apr 2026 | Ivan Hyep | CFO | Sell | 9,200 | 23.00 | 211,600 |
| 20. Apr 2026 | Claire Mazumdar | CEO | Sell | 15,000 | 23.61 | 354,150 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.